- Use of Digital Therapeutics (DTx) and Remote Continuous Data Monitoring (RCDM), provide patients with unobtrusive care and around-the-clock attention
- Common disorders such as Hashimoto’s Thyroiditis can have negative and life-changing impact on sufferers
- The co-founders GluCare both suffer from Hashimotos and found it frustrating to titrate medication to normalize thyroid hormone levels
- If ignored or left untreated, thyroid disorders can lead to cancer
Dubai, United Arab Emirates: Highly treatable and often curable thyroid disorders are negatively impacting the quality of life of thousands of people living in the UAE. Specialists at GluCare Integrated Diabetes Center have found that around 1 in 20 people in the Emirates live with some form of thyroid disorder, including the most common called Hashimoto’s thyroiditis.
Symptoms for disorders such as Hashimoto’s can manifest themselves in feelings of fatigue, depression, increased anxiety, or nervousness as well as trembling of the hands, hair loss, palpitations, constipation, menstrual disturbances, or an enlarged thyroid gland.
Hashimoto’s patients also live with a 30 per cent chance of the disorder developing into thyroid cancer, the sixth most common form of cancer and predicted to be the third most common in women by 2025. Hashimoto’s increases the likelihood of developing malignant thyroid nodules, solid or fluid-filled lumps that form in the thyroid, a small gland at the base of the neck. Nodules can be detected by physically examining the area, known as palpation, or ultrasound.
According to the Dubai Health Authority hundreds of patients a month seek treatment for thyroid disorders, with 30 per cent unaware of the condition.[1] Research has also found that many patients only seek treatments when they experience severe symptoms.[2]
Treatments for thyroid disorders are often uncomfortable, slow, and obstructive to a patient’s lifestyle. They include titrating medication, a process where drugs are applied gradually over several visits to a clinic. Dosages are based on a person’s weight, gender, or medical history. Thyroid ultrasounds are also used to detect anomalies such as nodules, although studies have shown that 70 per cent of ultrasounds return uncertain results.
As a result, many patients experience a lack of personalised treatment, slow access to appropriate doses of medication and indeterminate diagnoses that can lead to an unnecessary thyroidectomy to remove the thyroid.
GluCare’s pioneering use of digital therapeutics (DTx) and Remote Continuous Data Monitoring (RCDM) now offers patients new, unobtrusive forms of treatment plus round the clock attention by using Artificial Intelligence (AI).
Dr Ihsan Almarzooqi, GluCare Co-Founder and Managing Director, said: “As someone who suffers from Hashimoto's thyroiditis, I am only too aware how thyroid disorders can impact a person’s life. These disorders affect around five per cent of the UAE’s population so making the most effective and unobtrusive treatments available is important. As a patient, I was left extremely frustrated by the process of titrating medication. Time consuming, uncomfortable and restrictive, I felt there was a better alternative that could improve people lives.”
As leaders in data driven personalised medicine and the use of DTx and RCDM methods, GluCare utilises wearable AI-assisted bands to remotely monitor a patient’s reaction to thyroid medication as a function of heart rate, sleep patterns, skin temperature and weight changes all from the comfort of their home.
Practical and personalised, the clinical-grade band allows for remote observation of the process of titrating medication, with staff at GluCare regularly interacting with a patient while receiving online updates. The care team alongside the AI, continuously monitors the patient and are able to address areas of concern.
“GluCare’s use of DTx and RCDM treatments gives patients the freedom to live their lives while also experiencing high levels of care and attention. AI provides constant data so medical staff can assess, monitor and advise patients 24/7 with professional and empathetic care delivered in real time instead of waiting until the next appointment,” added Ali Hashemi, Co-Founder and Chairman of GluCare, who several years ago was also diagnosed with Hashimoto’s thyroiditis.
“The key to treating thyroid disorders such as Hashimoto's thyroiditis is early detection. There are identifiable risks to how they develop, including a family history of enlarged thyroid glands, exposure to radiation and certain hereditary and environmental issues. All of which makes a medical check-up, swift diagnosis and treatment essential.”
When it comes to diagnosing thyroid nodules, GluCare’s combination of an endocrinologist and AI provides a more sensitive and objective method of evaluation than examination or ultrasound. By using this advanced method, GluCare greatly increases the accuracy of thyroid imaging, reducing the need for painful tissue sample tests, collected via a needle in the patient’s throat, and removing the possibility of surgery in all but the most serious circumstances.
Patients experiencing symptoms of thyroid disorders are advised to call GluCare Integrated Diabetes Centre to book a consultation on +971 (0)4 220 1570 or visit the clinic on Al Wasl Road.
[1] https://www.dha.gov.ae/en/DHANews/Pages/DHANews656191865-14-01-2016.aspx
[2] https://thyroidresearchjournal.biomedcentral.com/articles/10.1186/s13044-018-0061-x
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
